膀胱癌放射治疗:ASTRO临床实践指南
美国放射肿瘤学会(ASTRO)基于系统文献综述与预设共识方法,针对膀胱癌放疗的4个关键问题制定推荐,涵盖保留膀胱的根治性放疗、放疗技术与剂量分割、术后放疗及转移/症状性疾病的姑息放疗,为临床实践提供循证指导。
要点
- 推荐多学科评估;cT2-4aN0M0肌层浸润性膀胱癌可选三联疗法(TMT)替代根治性膀胱切除术。
- TMT推荐同步放疗增敏全身治疗;远处进展高风险者推荐新辅助或诱导全身治疗。
- 推荐全膀胱全剂量放疗或未受累膀胱减量联肿瘤局部加量;选择性淋巴结放疗视肿瘤特征条件推荐。
核心结论
- 这些循证推荐指导膀胱癌放疗的临床应用,未来研究将进一步细化放疗适应证与作用。
研究设计与样本
- ASTRO召集工作组,基于系统文献综述和预设共识方法(含证据质量与推荐强度分级系统)制定指南。
- 指南针对4个关键问题:非转移性膀胱癌保留膀胱根治性放疗的适应证;完整膀胱局部或淋巴结阳性患者的放疗技术与剂量分割;术后放疗的适应证、技术与剂量分割;转移性或症状性非根治意图患者的膀胱或转移灶放疗适应证与剂量分割。
主要发现
- 鼓励所有患者接受多学科评估。
- 对选择性cT2-4aN0M0肌层浸润性膀胱癌患者,三联疗法(TMT)是根治性膀胱切除术的替代选择。
- TMT推荐同步放疗增敏全身治疗;远处进展风险较高者推荐新辅助或诱导全身治疗。
- 推荐全膀胱全剂量放疗,或未受累膀胱减量放疗联合部分肿瘤加量;选择性淋巴结放疗根据肿瘤特征条件推荐。
- 根治性膀胱切除术后(y)pT3-4或(y)pN+或切缘阳性的尿路上皮癌患者,条件推荐辅助放疗以改善局部区域控制。
关键数值与推荐
- cT2-4aN0M0肌层浸润性膀胱癌:TMT可作为根治性膀胱切除术的替代方案。
- 根治性膀胱切除术后(y)pT3-4或(y)pN+或切缘阳性:条件推荐辅助放疗用于局部区域控制。
- 推荐调强放疗(IMRT)联合每日图像引导,并提供靶区覆盖目标与正常组织剂量指导。
- 高负荷转移且局部症状性疾病,或非根治意图管理的局部区域疾病:推荐膀胱定向放疗用于局部控制和/或姑息。
临床怎么用
- 对选择性cT2-4aN0M0肌层浸润性膀胱癌,可与患者讨论TMT作为根治性膀胱切除术的替代。
- TMT时应同步放疗增敏全身治疗,远处进展高风险者考虑新辅助或诱导全身治疗。
- 放疗实施推荐IMRT联合每日图像引导,并按指南提供的靶区覆盖与正常组织剂量指导规划。
- 根治性膀胱切除术后高危((y)pT3-4、(y)pN+或切缘阳性)可条件推荐辅助放疗。
- 高负荷转移伴局部症状或非根治意图的局部区域疾病,可行膀胱定向放疗以局部控制或姑息。
局限性
- 指南基于系统文献综述与共识方法制定,未来研究将进一步细化放疗适应证与作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This guideline provides evidence-based recommendations addressing the indications for radiation therapy (RT) for bladder cancer in a variety of clinical settings, ranging from patients with localized disease to metastatic and symptomatic disease. METHODS: The American Society for Radiation Oncology convened a task force to address 4 key questions: (1) indications for bladder preservation with curative-intent RT, with or without systemic therapy, for patients with nonmetastatic bladder cancer; (2) appropriate RT techniques and dose-fractionation regimens for patients with intact, localized or node-positive bladder cancer; (3) indications, appropriate RT techniques, and dose-fractionation regimens for postoperative RT, with or without systemic therapy; and (4) indications and appropriate dose-fractionation regimens for RT to the bladder or sites of metastases for patients with metastatic or symptomatic bladder cancer being treated with noncurative intent. Recommendations are based on a systematic literature review and were created using a predefined consensus-based methodology with a system for grading evidence quality and recommendation strength. RESULTS: Multidisciplinary evaluation is encouraged for all patients. For select patients with cT2-4aN0M0 muscle-invasive bladder cancer, trimodal therapy (TMT) is an alternative to radical cystectomy. Concurrent radiosensitizing systemic therapy is recommended with TMT; neoadjuvant or induction systemic therapy is recommended for patients at higher risk of distant progression. RT to the whole bladder at full dose, or reduced dose to uninvolved bladder with a partial tumor boost, is recommended; elective nodal RT is conditionally recommended based on tumor characteristics. For patients with urothelial carcinoma who have (y)pT3-4 or (y)pN+ disease or positive margins postcystectomy, adjuvant RT is conditionally recommended for locoregional control. Intensity modulated RT with daily image guidance is recommended; target coverage goals and normal tissue dose guidance are provided. For patients with high-burden metastatic and locally symptomatic disease, or locoregional disease managed with noncurative intent, bladder-directed RT is recommended for local control and/or palliation. CONCLUSIONS: These evidence-based recommendations guide clinical practice on the use of RT for bladder cancer. Future studies will further refine the indications and role of RT in the management of these patients.
引用
- Ballas LK, Solanki AA, Baumann BC, et al. Radiation Therapy for Bladder Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2026. PMID: 42744092. doi:10.1016/j.prro.2026.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。